In Vitro ADME Testing: The Rise of Service Providers
It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early stage therapeutic candidates are able to make it past preclinical evaluation. According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity.
Current industry practices have widened the opportunity for companies providing in vitro ADME testing services
Presently, close to 100 firms are actively engaged in the in vitro ADME testing market, offering a wide variety of services to the pharmaceutical industry
With companies distributed across various geographies, the market landscape is highly fragmented; over time, offshoring has become a popular trend, along with a growing preference to partner with one stop shops
Majority of service providers are based in the developed regions; the market is characterized by the presence of established players and new entrants / small-sized companies
Companies involved in this domain are steadily expanding their capabilities in order to enhance their respective services portfolios and comply to evolving industry benchmarks
Stakeholders are actively expanding their existing capabilities to cater to the increasing demand; this is evident in the number of acquisitions (35+) reported over the past decade
Driven by a growing demand for effective therapeutics and an increase in drug discovery efforts across various therapeutic areas, the market is expected to witness sustained growth in future at a healthy CAGR of over 6%
The overall opportunity is anticipated to be well-distributed across various regions, type of therapeutic molecules and sponsors
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
Artificial Intelligence in Drug Discovery
Biopharma CRO: Fueling the research of novel biologics
ADC: The Excitement Continues to Build
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.